

Thomas Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11081190/publications.pdf>

Version: 2024-02-01

69
papers

15,053
citations

136740

32
h-index

138251

58
g-index

71
all docs

71
docs citations

71
times ranked

11103
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 994-1004. | 13.9 | 3,227 |
| 2 | Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2006, 355, 2408-2417. | 13.9 | 3,212 |
| 3 | Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2002, 346, 645-652. | 13.9 | 1,899 |
| 4 | Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. <i>Blood</i> , 2002, 99, 3530-3539. | 0.6 | 1,096 |
| 5 | Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937. | 0.6 | 943 |
| 6 | A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. <i>Blood</i> , 2002, 100, 1965-1971. | 0.6 | 534 |
| 7 | Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3. <i>Journal of Clinical Oncology</i> , 2010, 28, 4339-4345. | 0.8 | 442 |
| 8 | Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575. | 6.3 | 328 |
| 9 | FLT3 as a therapeutic target in AML: still challenging after all these years. <i>Blood</i> , 2010, 116, 5089-5102. | 0.6 | 321 |
| 10 | Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3110-3118. | 0.8 | 290 |
| 11 | Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. <i>Blood</i> , 2006, 107, 293-300. | 0.6 | 252 |
| 12 | Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. <i>Blood</i> , 2009, 114, 2386-2392. | 0.6 | 242 |
| 13 | AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. <i>Blood</i> , 2005, 106, 265-273. | 0.6 | 224 |
| 14 | Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke. <i>Acta Neuropathologica</i> , 2015, 129, 259-277. | 3.9 | 210 |
| 15 | Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- α treatment. <i>Blood</i> , 2008, 111, 1039-1043. | 0.6 | 195 |
| 16 | Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. <i>Blood</i> , 2007, 109, 4686-4692. | 0.6 | 141 |
| 17 | Efficacy and safety of imatinib in adult patients with c-kit α -positive acute myeloid leukemia. <i>Blood</i> , 2004, 103, 3644-3654. | 0.6 | 128 |
| 18 | The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome α -negative cells. <i>Cancer</i> , 2007, 110, 1509-1519. | 2.0 | 121 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. <i>Blood</i> , 2009, 113, 4074-4077. | 0.6 | 116 |
| 20 | A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. <i>Blood</i> , 2009, 113, 4063-4073. | 0.6 | 106 |
| 21 | Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). <i>Blood</i> , 2005, 105, 335-340. | 0.6 | 97 |
| 22 | Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7583-7593. | 0.8 | 89 |
| 23 | JAK2-V617F promotes venous thrombosis through β_1/β_2 integrin activation. <i>Journal of Clinical Investigation</i> , 2018, 128, 4359-4371. | 3.9 | 88 |
| 24 | Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. <i>Cancer</i> , 2007, 109, 1543-1549. | 2.0 | 57 |
| 25 | Directional mast cell degranulation of tumor necrosis factor into blood vessels primes neutrophil extravasation. <i>Immunity</i> , 2021, 54, 468-483.e5. | 6.6 | 56 |
| 26 | Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. <i>Blood</i> , 2018, 132, 67-77. | 0.6 | 54 |
| 27 | <i>Klebsiella oxytoca</i> causes colonization resistance against multidrug-resistant <i>K. pneumoniae</i> in the gut via cooperative carbohydrate competition. <i>Cell Host and Microbe</i> , 2021, 29, 1663-1679.e7. | 5.1 | 53 |
| 28 | Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. <i>Cancer</i> , 2007, 109, 907-914. | 2.0 | 51 |
| 29 | Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. <i>British Journal of Haematology</i> , 2012, 157, 483-492. | 1.2 | 46 |
| 30 | Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99. | 3.3 | 42 |
| 31 | Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells. <i>Nature Communications</i> , 2017, 8, 311. | 5.8 | 35 |
| 32 | Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. <i>Blood</i> , 2008, 112, 958-958. | 0.6 | 32 |
| 33 | Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial. <i>Annals of Hematology</i> , 2016, 95, 793-799. | 0.8 | 31 |
| 34 | Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. <i>Clinical Nutrition</i> , 2021, 40, 5298-5310. | 2.3 | 30 |
| 35 | Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719. | 3.3 | 28 |
| 36 | Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. <i>Leukemia</i> , 2020, 35, 2017-2029. | 3.3 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Evolutionarily Conserved Signaling Pathways: Acting in the Shadows of Acute Myelogenous Leukemia's Genetic Diversity. <i>Clinical Cancer Research</i> , 2015, 21, 240-248. | 3.2 | 25 |
| 38 | The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1698-1708. | 0.4 | 24 |
| 39 | DAPK-HSF1 interaction as a new positive feedback loop for TNF-induced apoptosis in colorectal cancer cells. <i>Journal of Cell Science</i> , 2014, 127, 5273-87. | 1.2 | 20 |
| 40 | Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. <i>Haematologica</i> , 2014, 99, e90-e93. | 1.7 | 14 |
| 41 | Leukemogenic potency of the novel FLT3-N676K mutant. <i>Annals of Hematology</i> , 2016, 95, 783-791. | 0.8 | 14 |
| 42 | Bis(1 <i>H</i> -indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A <i>in vitro</i> . <i>British Journal of Haematology</i> , 2009, 144, 865-874. | 1.2 | 11 |
| 43 | Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. <i>Annals of Hematology</i> , 2021, 100, 2387-2398. | 0.8 | 11 |
| 44 | Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. <i>Journal of Hematology and Oncology</i> , 2013, 6, 39. | 6.9 | 10 |
| 45 | The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells. <i>Cellular Signalling</i> , 2017, 35, 37-47. | 1.7 | 10 |
| 46 | Targeting RIPK1 in AML cells carrying FLT3-ITD. <i>International Journal of Cancer</i> , 2019, 145, 1558-1569. | 2.3 | 10 |
| 47 | Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study. <i>Annals of Hematology</i> , 2019, 98, 2729-2737. | 0.8 | 9 |
| 48 | Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8511-8511. | 0.8 | 9 |
| 49 | Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). <i>Annals of Hematology</i> , 2021, 100, 1569-1577. | 0.8 | 6 |
| 50 | 3,4-Diarylmaleimides—a novel class of kinase inhibitors—effectively induce apoptosis in FLT3-ITD-dependent cells. <i>Annals of Hematology</i> , 2012, 91, 331-344. | 0.8 | 5 |
| 51 | Central Venous Catheter-Related Bloodstream Infections in Obese Hematologic Patients. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 995-996. | 1.0 | 5 |
| 52 | Diagnostic and therapeutic challenges in extragonadal yolk sac tumor with hepatoid differentiation: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 79-82. | 0.4 | 5 |
| 53 | Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma. <i>European Journal of Cancer</i> , 2017, 75, 280-283. | 1.3 | 5 |
| 54 | Determination of a Cutoff Time Point for Prophylactic Exchange of Central Venous Catheters for Prevention of Central Venous Catheter-Related Bloodstream Infections in Patients with Hematological Malignancies. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 888-889. | 1.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | SDF1 β -induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLC β 1 and RhoA. <i>Haematologica</i> , 2019, 104, e288-e292. | 1.7 | 4 |
| 56 | Randomized Trial of a Supportive Psychotherapy for Parents of Adolescents and Young Adults With Hematologic Malignancies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-15. | 2.3 | 4 |
| 57 | Biased Low Incidence of Central Venous Catheter-Related Bloodstream Infections in Controlled Clinical Trials?. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 617-619. | 1.0 | 3 |
| 58 | Internal Tandem Duplication (ITD) in the Tyrosine Kinase Domain of FLT3 Displays Higher Oncogenic Potential in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5118-5118. | 0.6 | 1 |
| 59 | Primary ecthyma gangraenosum due to central venous catheter-related bloodstream infection with <i>Pseudomonas aeruginosa</i> . <i>Infection</i> , 2019, 47, 333-334. | 2.3 | 0 |
| 60 | Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 240-242. | 0.6 | 0 |
| 61 | Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1. <i>Blood</i> , 2008, 112, 2514-2514. | 0.6 | 0 |
| 62 | Different FLT3-ITD Integration Sites Are Associated with Differential Sensitivity to Tyrosine Kinase Inhibitors (TKI) In Vitro.. <i>Blood</i> , 2010, 116, 1709-1709. | 0.6 | 0 |
| 63 | A Novel Paradigm In Pharmacodynamics of Tyrosine Kinase Inhibitors: Pulse Treatment Induced Apoptosis Is Mediated by Intracellular Retention. <i>Blood</i> , 2010, 116, 1828-1828. | 0.6 | 0 |
| 64 | Allogeneic Stem Cell Transplantation of Mantle Cell Lymphoma - Results of the Propective Trials OSHO #060 and OSHO #074. <i>Blood</i> , 2011, 118, 2014-2014. | 0.6 | 0 |
| 65 | The Novel FLT3-N676K Mutant Induces Acute Leukemia Independently of the Inv(16) Chimeric Gene CBF β -MYH11. <i>Blood</i> , 2015, 126, 1383-1383. | 0.6 | 0 |
| 66 | Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2018, 132, 3063-3063. | 0.6 | 0 |
| 67 | In Vivo Blockade of Beta-1 and Beta-2 Integrin Activity Inhibits Splenomegaly in JAK2-V617F Positive Myeloproliferative Disease. <i>Blood</i> , 2018, 132, 1778-1778. | 0.6 | 0 |
| 68 | AXL Inhibition Represents a Novel Therapeutic Approach in Negative Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e630. | 1.2 | 0 |
| 69 | Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model. <i>HemaSphere</i> , 2022, 6, e717. | 1.2 | 0 |